Oral Bioavailability Articles & Analysis
12 news found
By leveraging the potential of small molecules, our clients can benefit from: Targeted Therapies - Small molecules can be designed to selectively modulate specific biological targets, allowing for precise intervention in disease processes. Oral Bioavailability - Many small molecules are suitable for oral administration, making them convenient and ...
In multiple animal species, OLX-07010, a novel small molecule inhibitor of tau self-association, demonstrated good oral bioavailability, with no significant adverse effects reported at the highest dose levels tested. ...
Abstract Project Summary Abstract The epidemic of cardiovascular diseaseCVDis a global phenomenon that remains the number one cause of death throughout the worldkilling nearlymillion people per yeara number that is expected to grow tomillion byA high cholesterol level is well known risk factors for heart diseaseAlthough blood cholesterol can be lowered using a number of marketed drugsof which ...
Recently, adding increased bioavailability excipients in drug formulations has gained widespread attention because they can alter the pharmacokinetics of drugs, ultimately resulting in improved bioavailability. ...
PAD4 inhibition a novel pathway to inhibit tumor metastasis and tumor growth Data presented at the American Association of Cancer Research Annual Meeting 2022 Jubilant Therapeutics Inc. a biopharmaceutical company advancing small molecule precision therapeutics to address unmet medical needs in oncology and autoimmune diseases, today announced data to be presented at the American ...
In a recent statement, the York-based CRO company CD Formulation announces the launch of tailored solutions for increased bioavailability excipients, which aims to tackle the issue of poor bioavailability, a long-lasting challenge in drug development. ...
Despite its good safety profile, the clinical utility of orally administered Betahistine is limited due to poor bioavailability. ...
The presentation titled “Development of Structurally Targeted Allosteric Regulators for the Treatment of Neuronopathic Gaucher Disease” demonstrated the following results: Orally bioavailable and brain-penetrant lead STARs have shown promising effects in relevant in vitro models of GD. ...
Shifa’s lead molecule, P-21, acts as a PCSK9/LDLR-antagonist to modulate the degradation of the LDLR in the liver, thereby regulating cholesterol homeostasis. With no orally bioavailable anti-PCSK9 drug having been FDA approved, P-21 shows promise as a potential new drug to treat hypercholesterolemic patients without the need for injections. ...
” The cytoTIL therapy is engineered using Obsidian’s cytoDRiVE platform technology, which precisely and reversibly controls protein expression and activity using FDA-approved orally bioavailable drugs. By leveraging regulated membrane-bound IL15 to drive antigen-independent expansion of T cells and transactivation of NK cells, cytoTIL therapy is ...
” About Renzapride Renzapride is an orally bioavailable small molecule with a dual mode of action. It is a full agonist at 5-HT4 receptors and stimulates gut motility. ...
” Shifa Biomedical successfully identified a potent orally bioavailable small molecule PCSK9 antagonist. This lead molecule (P-21) was identified through virtual screening of a million compounds and extensively validated through our in vitro as well as our functional cell-based assays. ...